Displaying drugs 1801 - 1825 of 2088 in total
SMART101
SMART101 is an investigational cell therapy comprising human allogeneic CD34-CD7+ T cell progenitors that were cultured ex vivo.
Investigational
AT1022
AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain.
AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect.
Investigational
OMS-103HP
OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.
Investigational
Tegavivint
Investigational
Matched Iupac: … N-[2,7-bis({[(3R,5S)-3,5-dimethylpiperidin-1-yl]sulfonyl})-10-(hydroxyimino)-9,10-dihydroanthracen-9- …
Brevenal
Investigational
TTX-MC138
TTX-MC138 is an antisense oligonucleotide targeting miR-10b. It is under investigation for the treatment of various metastatic cancers.
Investigational
HY10275
HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. HY10275 was rationally designed to...
Investigational
CMLVAX100
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Investigational
Seocalcitol
Investigational
ISA101b
ISA101b (peltopepimut-S) is a therapeutic vaccine against the HPV-specific E6/E7 oncoproteins.
Investigational
MIP-1095 I-123
123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).
Investigational
ANG1005
Investigational
CT103A
CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.
Investigational
Cinaciguat
Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)).
Investigational
Matched Description: … (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 …
SP1049C
SP1049C is a novel anthracycline chemotherapeutic agent containing doxorubicin and two nonionic pluronic block copolymers. It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. Preliminary data, in its first clinically tested indication,...
Investigational
ADX10059
ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety.
Investigational
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
GP-100 antigen
GP-100 antigen is under investigation in clinical trial NCT00006385 (Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma).
Investigational
ZVS101e
ZVS101e is a recombinant adeno-associated virus vector carrying human CYP4V2 gene.
Investigational
Mozafancogene autotemcel
RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A
Investigational
Displaying drugs 1801 - 1825 of 2088 in total